AKT2 and breast carcinoma: A cBioPortal [52] analysis shows ≈50% of breast cancers with genomic aberrations in PIK3CA, AKT1, AKT2, AKT3, and/or ESR1,suggesting relevance of this signaling axis in breast cancer (Figure 2).